首页> 外文OA文献 >Initial Experience With Single-Isocenter Radiosurgery to Target Multiple Brain Metastases Using an Automated Treatment Planning Software: Clinical Outcomes and Optimal Target Volume Margins Strategy
【2h】

Initial Experience With Single-Isocenter Radiosurgery to Target Multiple Brain Metastases Using an Automated Treatment Planning Software: Clinical Outcomes and Optimal Target Volume Margins Strategy

机译:用自动化治疗计划软件进行单依依赖者放射外科的初始经验,以使用自动化处理计划靶向多脑转移:临床结果和最佳目标体积利润率战略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose: Our purpose was to assess the clinical outcomes and target positioning accuracy of frameless linear accelerator single-isocenter multiple-target (SIMT) dynamic conformal arc (DCA) stereotactic radiosurgery (SRS) for multiple brain metastases (BM). Methods and Materials: Between October 2016 and September 2018, 31 consecutive patients ≥18 years old with 204 BM <3 cm in maximum size receiving SIMT DCA SRS were retrospectively evaluated. All plans were created using a dedicated automated treatment planning software (Brainlab, Munich, Germany), and treatments were performed with a Truebeam STx or a Novalis Tx (Brainlab and Varian Medical Systems, CA). The accuracy of setup and interfraction patient repositioning was assessed by Brainlab ExacTrac radiograph 6-dimensional image system and the risk of compromised target dose coverage evaluated. Brain control and overall survival were estimated by Kaplan-Meier method calculated from the time of SRS. Results: Fourteen patients were treated for 4 to 6 and 17 patients for 7 to 10 BM. The mean gross tumor volume (GTV) was 0.65 cm3 and the mean planning target volume (PTV) was 0.89 cm3. Mean V95 (the volume of the PTV covered by 95% of the prescription dose) and D95 (the prescription dose covering 95% of the PTV) were 99.5% and 21.1 Gy, respectively. With a median clinical follow-up of 11 months (range, 4-26 months), the 1-year survival was 68% and local control was 89%. As a consequence of plan isocenter residual errors, a loss of target coverage, defined as V95 < 95%, occurred in 28 PTVs (10 patients); using a 1 mm GTV-to-PTV margin, adequate dose coverage was maintained for all lesions. Conclusions: SIMT DCA SRS represents a fast and effective approach for patients with up to 10 BM. The dosimetric effects of residual set-up and intrafraction positioning errors are modest, although a GTV-to-PTV margin of 1 mm is recommended.
机译:目的:我们的目的是评估无框的临床结果和目标定位精度线性加速器单等角点的多目标(SIMT)动态共形弧(DCA)立体定向放射外科(SRS),用于多发性脑转移瘤(BM)。方法和材料:2016年10月和2018年9月间,31名连续的患者≥18岁,204 BM <3cm的最大尺寸接收SIMT DCA SRS进行回顾性评价。所有计划都采用专用的自动化治疗计划软件(Brainlab公司,德国慕尼黑)创建的,处理都是用Truebeam STx中或诺瓦利斯德克萨斯(Brainlab公司和瓦里安医疗系统,CA)进行。设置和次间患者重新定位的准确度是由的Brainlab ExacTrac射线照相6维图像系统和破坏靶剂量覆盖评估的风险评估。脑控制和总生存率通过从SRS的时间来计算的Kaplan-Meier方法估算。结果:14名患者进行了治疗4〜6和17例7〜10 BM。的平均肿瘤体积(GTV)为0.65厘米3,平均计划靶体积(PTV)为0.89厘米3。平均数V95(PTV所述的体积包括的处方剂量的95%)和D95(处方剂量覆盖PTV的95%)分别为99.5%和21.1戈瑞。随着11个月(4-26个月)的中位数临床随访,1年生存率为68%,局部控制率为89%。由于计划的等角点残余误差的结果,目标覆盖的损失,定义为V95 <95%,发生在28个PTVS(10名患者);使用1mm的GTV到PTV余量,足够剂量的覆盖下保持所有病变。结论:SIMT DCA SRS代表患者高达10 BM快速和有效的方法。残余设置和次内的定位误差的剂量测定影响是适度的,尽管1mm的GTV到PTV余量建议。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号